Latest news with #CartesianTherapeutics
Yahoo
4 days ago
- Business
- Yahoo
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Media Contact:David RosenArgot in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations
Revenue: US$1.10m (down 81% from 1Q 2024). Net loss: US$17.7m (loss narrowed by 69% from 1Q 2024). US$0.68 loss per share (improved from US$10.50 loss in 1Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 60%. Earnings per share (EPS) also surpassed analyst estimates by 7.9%. Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 22% from a week ago. We don't want to rain on the parade too much, but we did also find 5 warning signs for Cartesian Therapeutics (3 can't be ignored!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations
Revenue: US$1.10m (down 81% from 1Q 2024). Net loss: US$17.7m (loss narrowed by 69% from 1Q 2024). US$0.68 loss per share (improved from US$10.50 loss in 1Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 60%. Earnings per share (EPS) also surpassed analyst estimates by 7.9%. Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 22% from a week ago. We don't want to rain on the parade too much, but we did also find 5 warning signs for Cartesian Therapeutics (3 can't be ignored!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
10-05-2025
- Business
- Business Insider
Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities
In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price target of $40.00. The company's shares closed today at $9.90. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Evolus. According to TipRanks, Ear has an average return of 0.0% and a 38.83% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cartesian Therapeutics with a $36.80 average price target. RNAC market cap is currently $263.3M and has a P/E ratio of -0.20. Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RNAC in relation to earlier this year. Last month, TIMOTHY A SPRINGER, a Director at RNAC bought 149,075.00 shares for a total of $1,521,840.87.
Yahoo
05-05-2025
- Business
- Yahoo
Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential
We recently published a list of . In this article, we are going to take a look at where Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps. She also discussed the outlook for the category, saying that the earnings backdrop is essential. When we look back a year ago, investors were excited about small caps, as the earnings were recovering and the market was coming out of the 2023 earnings recession. Everyone expected that these stocks would see double-digit earnings growth by mid-last year, outpacing large caps. That got pushed out for over a year, and now the sector has sold off a lot. While we have gotten some potential good news on tariffs, there is still a lot of uncertainty, and we are in a backdrop where earnings revisions have still been negative. She opined that she would feel more comfortable if we were in a backdrop where there was confidence in earnings recovery because last earnings season, the commentary was a lot more negative from small-cap companies than large-cap companies. So far, this earnings season is still early for small caps, but guidance in both large and small has been weak. READ ALSO: and . Hall said that the sector would see a much better picture if earnings revisions turned around with higher confidence, and not only the tariffs were better than expected but also the economic backdrop was better. However, we are also in a place where economists think the Fed will stay on hold this year, and the Russell has been very sensitive to Fed expectations. Her outlook for small caps thus points towards a more credit-sensitive environment highly tethered to Fed expectations, with no anticipation of a rate cut this year. She also highlighted that looking at corporate commentary as small-cap reporting kicks off is important. Not all small caps are created equal, even when some people consider them to be so. Hall opined that this is definitely a year where you want to be selective in small caps, focusing on stocks with strong margins amid tariff uncertainty. She favored high-quality domestic stocks, steering clear of tariff and refinancing risks and focusing on stocks with positive revisions in this broad backdrop of negative revisions. There are groups of stocks that are more sensitive to tariffs, just as there are groups that are more global and domestic. Similarly, some groups are more levered with higher refinancing risks within small caps if the rate stays higher and credit spreads stay elevated. Therefore, she reasoned that she would stick with higher-quality stocks that are more profitable and have strong operating margins. Stocks with these characteristics have been some of the top performers within the industry amid tariff risks. From a sector perspective, if investors want to be more defensive, utilities screen well across the work, both in small and large caps. There will thus be opportunities in the segment, according to Hall, but one needs to be selective. She also expressed positive sentiments for mid-caps, which have been one of the best performers in the sector this year. They have seen much better revision trends, cleaner balance sheets, and fewer risks from potential earnings hits from tariffs than small caps because the latter have thinner margins and could see a greater hit. We sifted through stock screeners, financial media reports, and ETFs to compile a list of 30 small cap stocks and chose the top 11 with the biggest analyst upside potential as of May 2, 2025. We also included the number of hedge fund holders as of Q4 2024, which we sourced from Insider Monkey's database. The list is presented in ascending order of stocks' upside potential. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A close-up of a biotechnology machine working on an oncology therapy. Market Cap: $318.25 million Analyst Upside: 233.33% Number of Hedge Fund Holders: 7 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a clinical-stage biotechnology company that provides mRNA cell therapies to treat autoimmune diseases. The company operates in the development and research of cell therapy product candidates. It ranks second on our list of the best small-cap stocks to buy with the biggest upside potential. On April 10, Leerink Partners analyst Thomas Smith reiterated their bullish stance on the company, giving it a Buy rating. The analyst said that promising long-term data from Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Phase 2b trial of Descartes-08 for treating myasthenia gravis supports this rating. The results show durable and significant decreases in key efficacy endpoints, indicating a strong therapeutic effect. Most importantly, the data shows a favorable safety profile, reporting no new safety concerns like CRS or ICANS. According to the analyst, this supports the potential for outpatient administration without the need for lymphodepletion. Descartes-08 also holds a competitive market advantage, as trial results show a competitive depth of response and promising durability. Various other factors also point towards a positive outlook for Cartesian Therapeutics, Inc. (NASDAQ:RNAC), including the anticipation of further clinical data, including re-treatment and crossover experiences, and the upcoming Phase 3 AURORA trial. Overall, RNAC ranks 2nd on our list of top small cap stocks to buy with biggest upside potential. While we acknowledge the potential for RNAC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RNAC but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
